5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

Go Back to All Clinical Trials

5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

Brief description of study

This study will be a multi-site, double-blind, randomized clinical trial of the 5-HT2A receptor agonist psilocybin for smoking cessation. The current trial will be conducted across three sites with experience in conducting psilocybin research: Johns Hopkins University (JHU), the University of Alabama at Birmingham (UAB), and New York University Grossman School of Medicine (NYU). The proposed double-blind study will treat 66 participants (22 at each site), randomized to receive either: 1) oral psilocybin; 30 mg in session 1 and either 30 mg or 40 mg in session 2, with sessions 1 week apart (total 2 drug exposures separated by approximately one week); or 2) oral niacin; 150 mg in session 1 and either 150 mg or 200 mg in session 2, with sessions 1 week apart (total 2 drug exposures separated by approximately one week).

Clinical Study Identifier: s22-00503

ClinicalTrials.gov Identifier: NCT05452772

Principal Investigator: Michael P. Bogenschutz.

Other Investigators: Daniel Edward Roberts, Kelley O'Donnell.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies